A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
| Status: | Recruiting |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/11/2018 |
| Start Date: | December 8, 2017 |
| End Date: | January 2021 |
| Contact: | Eugene Kennedy, MD |
| Email: | clinicaltrials@linkp.com |
| Phone: | 515-598-2935 |
A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Adult Patients With Unresectable Stage III or Stage IV Malignant Melanoma
This is an adaptive clinical trial that includes a dose escalation phase followed by a
randomized controlled Phase 3 trial. The purpose of the dose escalation phase is to establish
the Phase 3 dose of indoximod in combination with pembrolizumab or nivolumab in subjects with
unresectable or metastatic melanoma and evaluate PK. Subsequently the efficacy, safety and
tolerability of indoximod plus pembrolizumab or nivolumab versus placebo plus pembrolizumab
or nivolumab will be studied in subjects with unresectable or metastatic melanoma in the
Phase 3 portion of the trial.
randomized controlled Phase 3 trial. The purpose of the dose escalation phase is to establish
the Phase 3 dose of indoximod in combination with pembrolizumab or nivolumab in subjects with
unresectable or metastatic melanoma and evaluate PK. Subsequently the efficacy, safety and
tolerability of indoximod plus pembrolizumab or nivolumab versus placebo plus pembrolizumab
or nivolumab will be studied in subjects with unresectable or metastatic melanoma in the
Phase 3 portion of the trial.
Inclusion Criteria:
- Have histologically- or cytologically-confirmed unresectable stage III or stage IV
melanoma not amenable to local therapy
- At least one radiologically measurable lesion as per RECIST 1.1
- Have documentation of V600-activating BRAF mutation status or consent to BRAF V600
mutation testing during the screening period.
- ECOG performance status 0 or 1
- Ability to ingest oral medications
Exclusion Criteria:
- Has Ocular Melanoma
- Has received prior systemic treatment for unresectable or metastatic melanoma (except
BRAF directed therapy).
- Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
IDO1 inhibitor or any other antibody or drug specifically targeting checkpoint
pathways other than anti-CTLA-4 which is permitted in the adjuvant setting.
- Has received prior adjuvant therapy, monoclonal antibody or an investigational agent
or device within 4 weeks or 5 half-lives (whichever is longer)
- Has received prior radiotherapy within 2 weeks of therapy.
- Is pregnant or breast-feeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of study treatment.
- Patients who have active, chronic, or on active treatment for Hep B or Hep C are
excluded.
We found this trial at
1
site
Click here to add this to my saved trials
